Premium
Suspected piperacillin‐tazobactam induced nephrotoxicity in the pediatric oncology population
Author(s) -
Pratt Jennifer A.,
Stricherz Melisa K.,
Verghese Priya S.,
Burke Michael J.
Publication year - 2014
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24720
Subject(s) - medicine , neutropenia , nephrotoxicity , piperacillin/tazobactam , febrile neutropenia , pediatric cancer , empiric therapy , piperacillin , acute kidney injury , population , tazobactam , complication , intensive care medicine , cancer , chemotherapy , pathology , kidney , pseudomonas aeruginosa , genetics , alternative medicine , environmental health , biology , bacteria
Neutropenic fever is a common complication of myelosuppressive therapy in pediatric oncology patients. Piperacillin‐tazobactam (PIP/TAZO) is a broad spectrum antibiotic used for empiric treatment of neutropenic fever. We describe four cases of suspected PIP/TAZO induced nephrotoxicity occurring in children with pediatric malignancies admitted to the hospital and treated for fever ± neutropenia. All patients exhibited acute renal injury shortly after PIP/TAZO administration with one of these cases having biopsy evidence of acute interstitial nephritis. These findings are suggestive of PIP/TAZO induced nephrotoxicity in pediatric oncology patients with fever ± neutropenia and that PIP/TAZO should be used judiciously in this population. Pediatr Blood Cancer 2014;61:366–368. © 2013 Wiley Periodicals, Inc.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom